| Yamada, Hiroshi |
| Recruiting | 3 | 300 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Chronic Migraine | 07/25 | 03/26 | | |
| Recruiting | 3 | 325 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Episodic Migraine | 11/25 | 11/26 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
| DONNET, Anne |
| Recruiting | 3 | 300 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Chronic Migraine | 07/25 | 03/26 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
| Itoi, Takao |
| Active, not recruiting | N/A | 51 | Japan | Hot AXIOS system used for EPASS | Boston Scientific Corporation | Gastric Outlet Obstruction | 12/24 | 03/25 | | |
| Gulati, Sheffali |
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS | Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. | Muscular Dystrophy, Duchenne | 10/26 | 10/26 | | |
STEER, NCT05089656: Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) |
|
|
| Active, not recruiting | 3 | 127 | Europe, US, RoW | OAV101, Zolgensma, AVXS-101, Sham control | Novartis Pharmaceuticals | Type 2 Spinal Muscular Atrophy | 11/24 | 02/25 | | |
| Recruiting | 3 | 325 | Europe, Japan, US, RoW | Galcanezumab, LY2951742, Placebo | Eli Lilly and Company | Episodic Migraine | 11/25 | 11/26 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
| Shimomura, Hideki |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
| Albrecht, Lorne E |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Completed | 2 | 30 | Canada, US | Daxdilimab, HZN-7734 | Amgen | Alopecia Areata | 08/23 | 01/24 | | |
| Pariser, David |
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
|
|
| Active, not recruiting | 3 | 186 | US | Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Superficial Basal Cell Carcinoma | 03/24 | 02/29 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia |
|
|
| Completed | 2 | 71 | US | TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution | Technoderma Medicines Inc., Therapeutics, Inc. | Alopecia, Androgenetic | 11/23 | 01/24 | | |
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 75 | US | LY3972406, Placebo | Eli Lilly and Company | Plaque Psoriasis | 04/25 | 07/25 | | |
NCT06645821: Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% |
|
|
| Recruiting | 1 | 15 | US | EVO101 | Virginia Clinical Research, Inc., Evommune, Inc. | Hidradenitis Suppurativa (HS) | 03/25 | 05/25 | | |
| Zhang, Jianzhong |
NCT06126965: Phase III Study of KX-826 With Adult Male Patients With AGA |
|
|
| Active, not recruiting | 3 | 740 | RoW | KX-826-（5%） BID, KX-826-5 mg(5%)60mL BID, Placebo | Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc. | Androgenetic Alopecia | 05/24 | 05/24 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT04839328: A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 3 | 306 | RoW | 60mg Hemay005, Hemay005 tablet, Placebo, placebo tablet | Tianjin Hemay Pharmaceutical Co., Ltd | Psoriasis | 10/22 | 07/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT05051761: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 425 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 12/24 | 12/24 | | |
NCT05676242: A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 12/24 | 12/24 | | |
NCT05667623: To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD |
|
|
| Recruiting | 3 | 270 | RoW | 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle | Otsuka Beijing Research Institute | Atopic Dermatitis (AD) | 07/24 | 01/25 | | |
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 510 | RoW | 611, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 09/25 | 05/26 | | |
NCT06277245: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. |
|
|
| Recruiting | 3 | 354 | RoW | LNK01001, Placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 09/25 | 11/25 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT06277765: Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis |
|
|
| Not yet recruiting | 3 | 180 | RoW | CM310, placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 05/25 | 05/25 | | |
NCT05255237: Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata |
|
|
| Active, not recruiting | 3 | 315 | RoW | Jaktinib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Alopecia Areata | 06/25 | 12/25 | | |
NCT05526222: A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 438 | RoW | Jaktinib Hydrochloride Tablet | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 06/25 | 09/25 | | |
NCT05265923: A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis |
|
|
| Completed | 3 | 500 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 10/23 | 12/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT06477536: Long-Term Safety and Efficacy of HB0034 in Subjects with Generalized Pustular Psoriasis |
|
|
| Recruiting | 2/3 | 33 | RoW | HB0034, Anti-IL-36R antibody,Recombinant Humanized anti-IL-36R Monoclonal antibody | Shanghai Huaota Biopharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 12/25 | 06/26 | | |
NCT06554509: Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis |
|
|
| Recruiting | 2/3 | 236 | RoW | SHR-1819 injection, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Prurigo Nodularis | 06/26 | 08/26 | | |
NCT06622824: To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia |
|
|
| Not yet recruiting | 2/3 | 756 | RoW | KX-826 0.5% BID, KX-826 1.0% BID, Vehicle (Placebo) applied BID | Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc. | Androgenetic Alopecia (AGA) | 10/27 | 06/28 | | |
NCT05940506: Phase II Study Evaluating the Efficacy and Safety of KX-826 |
|
|
| Completed | 2 | 120 | RoW | KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-2.5 mg (0.25%)/60 mL, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID, Placebo | Suzhou Kintor Pharmaceutical Inc, | Androgenetic Alopecia (AGA) | 07/21 | 08/21 | | |
NCT04539639: Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis |
|
|
| Completed | 2 | 166 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 05/22 | 05/22 | | |
NCT04893707: The Study of CM310 in Patients With Atopic Dermatitis |
|
|
| Completed | 2 | 127 | RoW | CM310, IL-4Rα monoclonal antibody | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 02/23 | 02/23 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT06085521: A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 2 | 150 | RoW | LNK01001 Dose A, LNK01001 Dose B, placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 06/23 | 06/23 | | |
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT05671432: The Study of CM326 in Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 240 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 12/23 | 12/24 | | |
D2570-201, NCT06278350: Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 160 | RoW | D-2570, Placebo | InventisBio Co., Ltd | Plaque Psoriasis | 12/24 | 03/25 | | |
NCT06231381: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 2 | 33 | RoW | HB0034, Recombinant Humanized anti-IL-36R Monoclonal antibody, Placebo | Shanghai Huaota Biopharmaceutical Co., Ltd. | Generalized Pustular Psoriasis (GPP) | 08/25 | 11/25 | | |
NCT06118866: A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects with Androgenetic Alopecia |
|
|
| Recruiting | 2 | 180 | RoW | placebo-Q2W, HMI-115-120mg-Q4W, HMI-115-240mg-Q4W, HMI-115, 240mg-Q2W | Hope Medicine (Nanjing) Co., Ltd | Androgenetic Alopecia | 12/24 | 12/24 | | |
NCT05671445: The Study of CM326 in Adult Subjects With Atopic Dermatitis |
|
|
| Recruiting | 2 | 100 | RoW | CM326 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 03/24 | 03/25 | | |
| Recruiting | 2 | 159 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT06509334: Trial of JYB1904 in Chronic Spontaneous Urticaria. |
|
|
| Recruiting | 2 | 135 | RoW | JYB1904, Omalizumab | Jemincare | Chronic Spontaneous Urticaria | 07/26 | 07/26 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 199 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 10/25 | 01/26 | | |
NCT05186922: The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 1/2 | 54 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 01/23 | 01/23 | | |
| Recruiting | 1/2 | 33 | RoW | Monoclonal antibody BAT6026, BAT6026, sodium chloride injection | Bio-Thera Solutions | Dermatitis, Atopic | 02/25 | 10/25 | | |
NCT06175143: A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. |
|
|
| Not yet recruiting | 1 | 40 | RoW | GR2002 injection | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Atopic Dermatitis | 10/24 | 10/24 | | |
| Contact, See Central |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
| Completed | 2 | 342 | Japan | VN-0200 | Daiichi Sankyo | Respiratory Syncytial Virus Infections | 04/23 | 02/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan |
|
|
| Active, not recruiting | 2 | 21 | Japan | Pexidartinib, TURALIO™, PLX3397 | Daiichi Sankyo Co., Ltd. | Tenosynovial Giant Cell Tumor | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | US, RoW | Q702, Pembrolizumab, KEYTRUDA® | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer | 10/25 | 06/26 | | |
| Recruiting | 1/2 | 130 | US, RoW | Q901, KEYTRUDA® (pembrolizumab) | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Advanced Cancer, Metastatic Cancer | 12/25 | 08/26 | | |
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor |
|
|
| Active, not recruiting | 1 | 78 | US | Q702 | Qurient Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Cancer | 12/24 | 02/25 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 40 | Canada, Japan, US | DS-1055a | Daiichi Sankyo Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Solid Tumor | 06/25 | 06/25 | | |
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 280 | Japan, US, RoW | HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 06/25 | 02/26 | | |
| Recruiting | 1 | 80 | Japan | DS-1471a | Daiichi Sankyo Co., Ltd. | Advanced Solid Tumor | 06/27 | 06/27 | | |
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 225 | US | Archival tissue specimen and immunohistochemistry staining | Daiichi Sankyo, Inc. | Non-small Cell Lung Cancer | 04/23 | 04/23 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
| Completed | 3 | 51 | Europe, Japan, US | BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 12/23 | 05/24 | | |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
| Completed | 3 | 270 | Europe, Canada, Japan, US, RoW | Placebo, Soticlestat, TAK-935 | Takeda | Lennox Gastaut Syndrome (LGS) | 01/24 | 01/24 | | |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
